- Home
- ASA vs TRML Comparison
ASA vs TRML Comparison
Compare ASA & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- TRML
- Stock Information
- Founded
- ASA 1958
- TRML 2021
- Country
- ASA United States
- TRML United States
- Employees
- ASA N/A
- TRML N/A
- Industry
- ASA Precious Metals
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- ASA Industrials
- TRML Health Care
- Exchange
- ASA Nasdaq
- TRML Nasdaq
- Market Cap
- ASA 381.4M
- TRML 419.1M
- IPO Year
- ASA N/A
- TRML N/A
- Fundamental
- Price
- ASA $20.82
- TRML $26.73
- Analyst Decision
- ASA
- TRML Strong Buy
- Analyst Count
- ASA 0
- TRML 5
- Target Price
- ASA N/A
- TRML $61.80
- AVG Volume (30 Days)
- ASA 46.6K
- TRML 302.5K
- Earning Date
- ASA 10-15-2024
- TRML 11-12-2024
- Dividend Yield
- ASA 0.14%
- TRML N/A
- EPS Growth
- ASA N/A
- TRML N/A
- EPS
- ASA 3.25
- TRML N/A
- Revenue
- ASA $2,356,231.00
- TRML N/A
- Revenue This Year
- ASA N/A
- TRML N/A
- Revenue Next Year
- ASA N/A
- TRML N/A
- P/E Ratio
- ASA $6.38
- TRML N/A
- Revenue Growth
- ASA N/A
- TRML N/A
- 52 Week Low
- ASA $12.80
- TRML $9.18
- 52 Week High
- ASA $21.51
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- ASA 55.60
- TRML 80.91
- Support Level
- ASA $20.52
- TRML $23.85
- Resistance Level
- ASA $21.38
- TRML $27.00
- Average True Range (ATR)
- ASA 0.37
- TRML 1.65
- MACD
- ASA -0.04
- TRML 0.28
- Stochastic Oscillator
- ASA 46.45
- TRML 96.68
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation primarily through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.